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Objective To examine whether attention-deficit/hyperactivity disorder (ADHD) stimulant medication modified the
linear growth response to growth hormone (GH) treatment in children enrolled in the American Norditropin Studies:
Web-Enabled Research Program.
Study design Short, GH treatment-naive children with or without GH deficiency (GHD) received GH therapy. A
subset also received ADHD stimulant medication (n = 1190), and others did not (n = 7230). Linear mixed models
(adjusted means) examined height SDS (HSDS) and body mass index (BMI) SDS from baseline through year 4. An-
alyses were repeated with ADHD groups matched for baseline age, height, weight, BMI, and sex. Groups with and
without GHD were compared between ADHD groups.
Results Adjusted change in HSDS for the group receiving ADHD stimulant medication was slightly lower than that
for patients not receiving stimulant medication at years 1 to 4 (P < .05). However, adjusted change in HSDS was
similar between children receiving and not receiving ADHD stimulant medication when matched for baseline mea-
surements. At year 4, 86.7% of patients receiving ADHD stimulant medication, 86.8% of total patients not receiving
ADHD stimulant medication, and 84.6% of matched group patients not receiving ADHD stimulant medication
achieved HSDS >2. Year 4 adjusted change in BMI SDS was greater in the patients receiving ADHD stimulant
medication compared with both groups not receiving ADHD stimulant medication (P < .05). Patients with GHD
showed comparable differences in adjusted change in BMI SDS among the ADHD groups at year 4, whereas pa-
tients without GHD showed no significant differences.
Conclusions ADHDmedication did not affect the linear growth response of children treated with GH when those
receiving or not receiving ADHD stimulant medication were matched for baseline measurements. Underlying rea-
sons for the observed greater increase in BMI in patients with GHD concomitantly treated with ADHD medication
remain to be elucidated. (J Pediatr 2015;167:1389-96).
Trial registration ClinicalTrials.gov: NCT01009905.
R
ecombinant human growth hormone (GH) treatment is approved by the US Food and Drug Administration for children
with linear growth failure or short stature due to GH deficiency (GHD), idiopathic short stature (ISS), Turner syndrome,
Noonan syndrome, Prader-Willi syndrome, short stature homeobox-containing gene deficiency, chronic renal disease,
and children born small for gestational age (SGA) with no catch-up growth by 2 to 4 years of age.1,2 The goal of GH treatment
across pediatric indications is to improve linear growth in childhood and to achieve an adult height within the normal range.3,4
To achieve optimal height outcomes, it is important to consider potential comorbid conditions that may influence growth
and GH treatment response. Attention-deficit/hyperactivity disorder (ADHD) may be an important growth-influencing co-
morbidity during GH treatment because of the frequent use of psychostimulants as first-line psychopharmacologic therapy.5,6
Some children taking ADHD stimulant medications experience a loss of appetite, weight loss, and a decrease in height andFrom the 1Departments of Pediatric Endocrinology and
Metabolism, Cincinnati Children’s Hospital Medicalweight increments.7-9 A review of studies examining growth in children with
ADHD who receive stimulant medication suggested that in children with short
stature, a minor medication effect on growth velocity could be clinically impor-
tant.10 Two previous studies using data from the National Cooperative GrowthCenter, University of Cincinnati College of Medicine,
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ADHD Attention-deficit/hyperactivity
disorder
ANSWER American Norditropin Studies:
Web-Enabled Research
BMI Body mass index
GH Growth hormone
GHD GH deficiency
HSDS Height SDS
IGF-I Insulin-like growth factor-I
ISS Idiopathic short stature
KIGS Pfizer International Growth
Study
NCGS National Cooperative Growth
Study
SGA Small for gestational age
DBMI SDS Change in BMI SDS
DHSDS Change in height SDS
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stimulant medications do not have clinically significant dif-
ferences in growth compared with children not taking stim-
ulant medications during GH treatment.6,11 A study from the
Pfizer International Growth Study (KIGS) registry found
1-year GH therapy growth response in stimulant-treated
children with ADHD and GHD was significantly less than
the expected growth in children with GHD based on previ-
ously developed growth prediction statistical models.12,13
In the KIGS study, no significant differences between chil-
dren with stimulant-treated ADHD or without ADHD
were seen in children with ISS, SGA, or Turner syndrome us-
ing growth prediction models. Additionally, a study of short
SGA children treated with GH with or without methylpheni-
date treatment for ADHD showed no negative effect of stim-
ulant treatment on adult height.14 Thus, the potential effects
of ADHD stimulant medications on linear growth and weight
responses among pediatric GH treatment indications remain
to be clarified. The current study examines the effect of
ADHD medications on change in height SDS (DHSDS)
and change in body mass index (BMI) SDS (DBMI SDS)
over a 4-year period of GH therapy in pediatric patients
enrolled in the American Norditropin Studies: Web-
Enabled Research (ANSWER) Program.
Methods
Data for this analysis were obtained from the ANSWER Pro-
gram, a non-interventional study (ClinicalTrials.gov:
NCT01009905) collecting long-term effectiveness and safety
information from patients treated with Norditropin (soma-
tropin [rDNA origin] injection, Novo Nordisk A/S, Bags-
vaerd, Denmark)15 in the US. The ANSWER Program
(utilizing the research Web-based platform, NovoNet) has
collected effectiveness and safety information on >13 000 pe-
diatric patients since 2002.16 Participation within the
ANSWER Program is at the discretion of the participating
physicians and includes pediatric patients with diagnostic
conditions of short stature or growth failure treated with
GH. Participating physician investigators entered patient his-
tories and physical examination data using the Web-based
data entry tool. The current study analyzed only GH
treatment-naive patients age #18 years with the diagnosis
of GHD (as determined by the participating physician,
including isolated/idiopathic or multiple pituitary hormone
deficiency), orwith non-GHD short stature, includingTurner
syndrome, Noonan syndrome, SGA, ISS, Prader-Willi syn-
drome, and other short-stature conditions (eg, chronic renal
disease, short stature homeobox-containing gene deficiency).
Enrollment in this patient registry is solely at the discretion of
the participating physicians and for patients in whom Nordi-
tropin is prescribed for treatment of appropriate conditions
of growth failure and short stature both within and outside
the Norditropin label. All participants provided written
informed consent prior to entry into the study and were
free to discontinue treatment at any time. The collected
data were anonymous. The study protocol was approved by1390an institutional review board and carried out in accordance
with Good Pharmacoepidemiologic Practice guidelines.
Patients were categorized as those receiving ADHDmedica-
tion (n = 1190), including dextroamphetamine and amphet-
amine, amphetamine, pemoline, methylphenidate, or other;
and those not receiving ADHD medication (n = 7230). Data
analyses compared patients receiving and not receiving stim-
ulant medication. Patients who did not have the data entry
field completed, indicating treatment with or without
ADHD medication (n = 969), were excluded from the com-
parisons. Clinical data recorded at baseline included age,
sex, height, weight, BMI SDS, height SDS (HSDS), insulin-
like growth factor-I (IGF-I) SDS, and bone age. HSDS and
BMI SDS were calculated according to the standard formulas
provided by the Centers for Disease Control and Prevention.17
All IGF-I values were measured locally and entered into the
database. Transformation of IGF-I data into IGF-I SDS was
then made based on the age- and sex-related normative refer-
ence values of Brabant et al.18 Clinical data collected at
4 months and years 1 through 4 of GH treatment included
HSDS, BMI SDS, and GH dose.
Statistical Analyses
Data were collected at 4 months within a1-month window
and at 1 through 4 years within a 3-month window. To
eliminate potential data errors, patients with data outliers
were excluded from the analysis when key variables (age,
height, weight, etc.) were missing or deemed implausible. De-
mographic characteristics and descriptive data are presented
as mean SD or percentages. Children younger than 2 years
of age were excluded from the BMI analyses because of a lack
of appropriate reference data for this age group. Compari-
sons between the above groups of DHSDS and DBMI SDS
from baseline to 4 months and years 1 through 4 were sum-
marized using arithmetic means (unadjusted DHSDS and
DBMI SDS) and least squares means (adjusted DHSDS and
DBMI SDS). To compare DHSDS and DBMI SDS between
the groups at each time point, ANCOVA with ADHD medi-
cation use as the fixed effect and baseline HSDS value or BMI
value as the covariate was performed. For the analysis of
DHSDS, the ANCOVA model also included age and sex as
covariates. Across the study time points, the ANCOVA
models used different subcohorts of the subject population
because of varied missing data at each time point. Fisher
exact test was used to compare the proportion of patients
achieving HSDS >2 (ie, within normal range) at year 4.
Because of differences in baseline age and associated mea-
surements between the patients receiving or not receiving
ADHD stimulant medication, additional analyses were con-
ducted with a subgroup of patients not receiving ADHD
stimulant medication who were matched to the baseline
age, height, weight, BMI, and sex of the patients receiving
ADHD stimulant medication. Results are first presented as
comparison between the total group receiving ADHD stimu-
lant medication and total group not receiving ADHD medi-
cation. Results are then presented comparing the total group
receiving ADHD stimulant medication with the matchedRose et al
December 2015 ORIGINAL ARTICLESgroup not receiving ADHD stimulant medication, matched
for baseline age, height, weight, BMI, and sex. These compar-
isons between groups receiving and not receiving ADHD
stimulant medication are presented for all diagnostic cate-
gories together followed by results for patients with GHD,
as well as for patients without GHD. An ANCOVA model
with ADHD classes and diagnosis category as fixed effects
and baseline HSDS value or BMI value, age, and sex as cova-
riates was conducted to assess the different distribution of
GH-related diagnoses within the groups receiving and not
receiving ADHD stimulation medication on HSDS and
BMI SDS outcomes.
Results
The analyses included 1190 GH treatment-naive patients tak-
ing ADHD medication and 7230 patients who did not take
ADHD medication. Baseline demographic and clinical char-
acteristics are summarized in Table I. Patients receiving
ADHD stimulant medication were, on average, older than
patients not receiving ADHD medications, included a
greater proportion of male patients, and were slightly taller
(absolute height in cm) and heavier than patients not
receiving ADHD medications. These baseline differences
were neutralized when compared with a subgroup of
patients not receiving ADHD stimulant medication
matched for age, sex, height, weight, and BMI. Significant
differences in baseline HSDS and IGF-I SDS remained
between the group receiving ADHD stimulant medication
and the match group not receiving stimulants. Patients
diagnosed with GHD made up the largest proportion of
both the total and matched groups receiving and notTable I. Baseline demographic and clinical characteristics
Total group not receiving ADHD
stimulant medication
M ± SD (N)
Age, y 10.2  4.0 (7230)*
Male, n (%) 4743 (65.6)*
Height, cm 125.5  23.3 (7230)*
HSDS 2.2  1.0 (7230)*
Weight, kg 30.6  15.4 (7228)*
BMI, kg/m2 18.1  4.0 (7185)*
IGF-I SDS 1.6  1.6 (5304)*
Bone age, y 9.2  3.6 (5637)*
Psychotropic medication† n (%) 30 (0.4)
Diagnosis, n (%)
GHDz 3726 (52)*
MPHD 333 (5)*
ISS 935 (13)
SGA 541 (7)
Turner syndrome 397 (5)*
Noonan 96 (1)
CRD 38 (0.5)
PWS 50 (0.7)
SHOX 9 (0.1)
Other 1105 (15)
CRD, chronic renal disease; MPHD, multiple pituitary hormone deficiency; PWS, Prader-Willi syndro
*P < .001 between groups receiving and not receiving ADHD stimulant medication.
†Psychotropic medications taken by patients for $1 dose.
zAll of the patients with GHD in each of the 3 ADHD groups who had GH stimulation test results sh
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from the ANSWER Program, a Non-Interventional Studyreceiving ADHD stimulant medication (Table I). Tanner
staging at baseline for patients diagnosed with GHD
showed Stage I pubertal development for 68% (484/712) of
the patients with GHD receiving ADHD stimulant
medication, 60% (2224/3726) of the total group of patients
with GHD not receiving ADHD stimulant medication, and
56% (372/660) of the matched group of patients not
receiving ADHD stimulant medication.
HSDS Outcomes
The effects of GH treatment on DHSDS over 4 years of treat-
ment are presented in the Figure and Table II. Both the
unadjusted and adjusted mean DHSDS were lower in the
group receiving ADHD stimulant medication compared
with the total group not receiving ADHD stimulant
medication at 4 months and years 1 through 4 (P < .05).
Importantly, unadjusted and adjusted DHSDS did not
significantly differ between the group receiving ADHD
stimulant medication and the matched group not receiving
ADHD stimulant medication at years 1 through 4. These
analyses were repeated using baseline bone age in place of
chronological age as a covariate and similar results were
found in the comparisons of matched groups receiving and
not receiving ADHD stimulant medication.
Likewise, in patients diagnosed with GHD, although
adjusted mean DHSDS was lower in the group receiving
ADHD stimulant medication compared with the total group
not receiving ADHD stimulant medication at 4 months and
years 1 through 4 (P < .01), this difference disappeared when
patients receiving and not receiving ADHD stimulant medi-
cation were matched for age, sex, height, weight, and BMI.
The adjusted DHSDS in the group with GHD receivingTotal group receiving ADHD
stimulant medication
M ± SD (N)
Matched group not receiving
ADHD stimulant medication
M ± SD (N)
11.7  2.5 (1190) 11.8  3.1 (1188)
984 (83) 1010 (85.0)
132.8  14.5 (1190) 133.8  17.6 (1188)
2.3  0.8 (1190) 2.2  0.9 (1188)*
32.3  13.2 (1190) 33.1  12.4 (1188)
17.6  3.9 (1188) 17.8  3.4 (1188)
2.2  1.5 (903) 1.9  1.6 (897)*
9.8  2.8 (1024) 10.3  3.1 (978)
57 (4.8) 5 (0.4)
712 (60) 660 (56)
16 (1) 27 (2)
155 (13) 169 (14)
79 (7) 78 (7)
20 (2) 18 (2)
13 (1) 23 (2)
4 (0.3) 4 (0.3)
2 (0.2) 1 (0.1)
2 (0.2) 3 (0.3)
187 (16) 205 (17)
me; SHOX, short stature homeobox-containing gene.
owed GH stimulation testing peak hormone <10 ng/mL, thus meeting criteria for GHD.
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Figure. HSDS and DHSDS in A, total group receiving ADHD stimulant medication, B, total group not receiving ADHD medi-
cation, and C, matched group not receiving ADHD medication but receiving GH treatment. Unadjusted HSDS (mean  SD) at
baseline, 4months, and year 1 through 4 are shown on the left side of each panel. AdjustedDHSDS (least squaremean estimates
SE) derived fromANCOVA analyses with baseline HSDS, age, and sex as covariates at 4months and year 1 through 4 is shown
on the right side of each panel.
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increased to 1.310 at year 4, whereas the adjusted DHSDS
in the total group not receiving ADHD stimulant medication
was 0.567 at year 1 and increased to 1.529 at year 4. The
adjusted DHSDS in the matched group with GHD not
receiving ADHD stimulant medication was 0.491 at year 1
and 1.298 at year 4.Table II. Change in HSDS and BMI SDS in patients receivin
Total group receiving ADHD
stimulant medication †
Total group not receiving
ADHD stimulant medicatio
N = 1190 N = 7230
Adjusted
LSM (N)
Unadjusted M ± SD
(N)
Adjusted
LSM (N)
Unadjusted M ±
(N)
DHSDS
4 mo 0.16* (511) 0.14  0.2* (514) 0.20 (2882) 0.20  0.3 (29
1 y 0.49* (801) 0.46  0.4* (801) 0.55 (4667) 0.55  0.5 (46
2 y 0.89* (596) 0.86  0.5* (596) 0.98 (3317) 0.98  0.7 (33
3 y 1.16* (401) 1.16  0.6* (401) 1.26 (2157) 1.25  0.8 (21
4 y 1.32* (240) 1.33  0.6* (240) 1.45 (1205) 1.44  0.9 (12
DBMI SDSz
4 mo 0.04* (509) 0.02  0.5* (509) 0.04 (2758) 0.03  0.6 (27
1 y 0.04 (797) 0.12  0.6 (797) 0.06 (4448) 0.05  0.7 (44
2 y 0.17 (593) 0.28  0.9 (593) 0.17 (3137) 0.15  0.8 (31
3 y 0.28 (397) 0.43  1.0 (397) 0.23 (2025) 0.21  0.9 (20
4 y 0.40* (239) 0.59  1.1* (239) 0.28 (1107) 0.25  1.0 (11
LSM, least square mean.
*P < .05 between total group receiving or not receiving ADHD stimulant medication, or matched gr
†The group receiving ADHD stimulant medication included the same patients in both analyses; how
variable estimates of the predicted values that use all of the available data in the analysis.
zPatients younger than 2 years of age were excluded.
1392In patients without GHD diagnoses, the adjusted DHSDS
was lower in the group receiving ADHD stimulant medica-
tion at year 1 (P = .026) compared with the total group not
receiving ADHD stimulant medication. No significant differ-
ence was found at 4 months and years 2 through 4. The
adjusted DHSDS in the group of patients without GHD
receiving ADHD stimulant medication was 0.445 at year 1g or not receiving ADHD stimulant medication
n
Total group receiving ADHD
stimulant medication †
Matched group not receiving
ADHD stimulant medication
N = 1190 N = 1188
SD Adjusted
LSM (N)
Unadjusted M ± SD
(N)
Adjusted
LSM (N)
Unadjusted M ± SD
(N)
13) 0.14* (511) 0.14  0.2* (514) 0.18 (470) 0.18  0.2 (474)
67) 0.46 (800) 0.46  0.4 (800) 0.49 (761) 0.48  0.4 (761)
17) 0.86 (595) 0.86  0.5 (595) 0.92 (543) 0.90  0.6 (543)
57) 1.15 (400) 1.16  0.6 (400) 1.18 (332) 1.15  0.7 (332)
05) 1.33 (239) 1.34  0.6 (239) 1.36 (153) 1.34  0.6 (153)
58) 0.00* (509) 0.02  0.5* (509) 0.08 (468) 0.09  0.6 (468)
48) 0.09 (797) 0.12  0.6 (797) 0.12 (754) 0.13  0.7 (754)
37) 0.22 (593) 0.28  0.9 (593) 0.24 (536) 0.25  0.7 (536)
25) 0.34 (397) 0.43  1.0 (397) 0.24 (325) 0.26  0.9 (325)
07) 0.47* (239) 0.59  1.1* (239) 0.28 (152) 0.29  0.8 (152)
oups receiving or not receiving ADHD stimulant medication.
ever, the ANCOVA LSM estimates differ in the 2 analyses because of differences in the model
Rose et al
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total group not receiving ADHD stimulant medication was
0.501 at year 1 and increased to 1.298 at year 4. As with the
patients with GHD, no significant differences in the adjusted
DHSDS were found between the group receiving ADHD
stimulant medication and the matched group without
GHD not receiving ADHD stimulant medication.
The proportion of patients achieving HSDS >2 (ie,
within normal range) at year 4 was not significantly different
in the groups receiving and not receiving ADHD stimulant
medication at year 4 (receiving: 86.7%, total group not
receiving: 86.8%, matched group not receiving: 84.6%).
This was also observed in patients with GHD (receiving:
86.8%, total group not receiving: 89.6%, matched group
not receiving: 87.8%) and in patients without GHD
(receiving: 86.7%, total group not receiving: 83.1%, matched
group not receiving: 79.3%).
BMI Outcomes
The effects of GH treatment on DBMI SDS over 4 years of
treatment are presented in Table II. Unadjusted and
adjusted mean DBMI SDS from baseline was greater in the
total group not receiving ADHD stimulant medication and
matched group compared with the group receiving ADHD
stimulant medication at 4 months (P < .05), but was
greater in the group receiving ADHD stimulant medication
compared with the total and matched groups not receiving
ADHD stimulant medication at year 4 (P < .05). Similarly,
in patients diagnosed with GHD, adjusted DBMI SDS was
greater in the total group not receiving ADHD stimulant
medication (0.03) and matched group (0.10) compared
with the group receiving ADHD stimulant medication at
4 months (P < .01) (0.07 in the total group analysis and
0.04 in the matched group analysis), but was greater in
the group receiving ADHD stimulant medication at year 4
(P < .05) (0.41 in the total group analysis and 0.47 in the
matched group analysis) compared with the total (0.25)
and matched (0.23) groups not receiving ADHD stimulant
medication. Among patients without GHD diagnoses, there
were no significant differences between the total and
matched groups receiving and not receiving ADHD
stimulant medication in adjusted DBMI SDS from baseline
at any time point (P $ .05).
A sensitivity analysis adjusting for GH-related diagnosis
showed no impact of the different distribution ofTable III. GH dose in patients receiving or not receiving AD
Total group not receiving ADHD
stimulant medication
M ± SD mg/kg/d (N)
Total
st
M
Baseline 48  13 (6589)
4 mo 48  12 (2645)
1 y 50  14 (4223)
2 y 51  16 (2896)
3 y 51  17 (1796)*
4 y 50  17 (969)
*P < .05 between groups receiving or not receiving ADHD stimulant medication.
Attention-Deficit/Hyperactivity Disorder Medication Treatment Im
from the ANSWER Program, a Non-Interventional StudyGH-related diagnoses within the groups receiving and not
receiving ADHD stimulant medication on HSDS and BMI
SDS outcomes.
GH Dose and IGF-I Levels
Mean starting doses of GH were not different between pa-
tients receiving and not receiving ADHD stimulant medica-
tion and there was no pattern to GH doses over time between
groups. At year 3, the mean GH dose was slightly higher in
the group receiving ADHD stimulant medication group
compared with the total group not receiving ADHD medica-
tion (P = .029; Table III). The mean GH dose of the matched
group not receiving ADHD stimulant medication was
slightly higher than the group receiving ADHD medication
at year 1 and year 2 (P < .05; Table III). Patients diagnosed
with GHD showed similar mean GH doses in total and
matched groups receiving and not receiving ADHD
stimulant medication at years 1 through 4 (data not
shown). Among patients without GHD diagnoses, the
mean GH dose was slightly higher in the total group not
receiving ADHD stimulant medication (52.5 mg/kg/d) and
matched group (53.6 mg/kg/d) compared with the group
receiving ADHD stimulant medication (50.7 mg/kg/d;
P < .03) at year 1. The mean GH dose was slightly higher
in the group receiving ADHD stimulant medication
(55.7 mg/kg/d) compared with the total group not receiving
ADHD medication (52.3 mg/kg/d; P = .035) at year 3. The
average length of GH treatment was similar for the total
group receiving ADHD stimulant medication
(29.9  22.5 months), total group not receiving ADHD
medication (27.3  21.5 months), and matched group not
receiving ADHD medication (25.5  19.1 months).
The mean IGF-I SDS levels increased from baseline to
levels within the upper normal range without a significant
difference between the total and matched groups receiving
and not receiving ADHD stimulant medication at year 4.
Additionally, patients diagnosed with GHD and short stature
without GHD diagnoses showed similar IGF-I SDS levels in
the total and matched groups receiving and not receiving
ADHD stimulant medication at year 4 (data not shown).
Discussion
The possible influence of ADHD stimulant medication on
the linear growth response to pediatric GH treatment is notHD stimulant medication
group receiving ADHD
imulant medication
± SD mg/kg/d (N)
Matched group not receiving
ADHD stimulant medication
M ± SD mg/kg/d (N)
48  12 (1102) 48  12 (1070)
48  11 (467) 49  11 (435)
50  13 (749) 51  14 (683)*
52  15 (534) 54  17 (459)*
53  16 (345) 53  17 (263)
53  16 (209) 52  15 (123)
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with ADHD medications in children referred for GH treat-
ment.6,19,20 To address this important question, the current
study examined a large sample of pediatric patients from
the ANSWER Program with diverse diagnostic indications
for GH treatment over a 4-year follow-up period. A compar-
ison of the total group of patients not receiving ADHDmedi-
cation with those receiving ADHD medications revealed a
lower DHSDS increment in patients receiving ADHD medi-
cations. However, the magnitude of the difference in adjusted
mean DHSDS between these 2 groups was small, ranging
from 0.04 at 4 months to 0.12 at year 4. Importantly, these
differences were no longer evident when the group not
receiving ADHD stimulant medication wasmatched with pa-
tients receiving ADHD medication for baseline age, height,
weight, BMI, and sex, indicating that when adequately
matched for baseline measurements, there was no negative
impact of ADHD medication observed on the response to
GH treatment. The majority of patients in the groups
receiving and not receiving ADHD stimulant medication
achieved a height within the normal range (>2 SDS), and
DHSDS from baseline to year 4 was >1 SDS for all groups
(receiving: 1.32 SDS; total group not receiving: 1.45 SDS;
matched group not receiving: 1.36 SDS). Similar results
were observed in the analyses of patients with and without
GHD.
In the analyses within patients with GHD, no significant
differences in GH dose were found between the groups
receiving and not receiving ADHD stimulant medication.
Among the patients with short stature without GHD, the to-
tal and matched groups not receiving ADHD stimulant
medication received slightly higher mean GH doses at year
1 compared with the group receiving ADHD medication,
whereas the group receiving ADHD medication had higher
GH doses at year 3 compared with the total group not
receiving ADHD medication. Despite these observed differ-
ences, mean GH dose over time did not follow a differenti-
ated pattern among the ADHD groups. This also reflects
the cross-sectional nature of these data. These slight differ-
ences in GH dose are consistent with careful dose adjustment
depending on individual growth responses.
Contrary to previous studies that showed a potential loss
of appetite and attendant weight loss in children receiving
ADHD stimulant medication, the current study suggests
that GH treatment may stabilize BMI in patients who are
receiving stimulant medication for comorbid ADHD.7-9
Although there are other factors that could potentially affect
BMI, the effects seen here within the context of ADHD treat-
ment may indicate a counter-effect of GH to the appetite
suppression and weight loss that can occur alongside stimu-
lant medication treatment of ADHD. Analyses of DBMI SDS
showed no differences between the groups without GHD
receiving and not receiving ADHD stimulant medication;
however, among all patients and among patients with
GHD, DBMI SDS was greater in the group receiving
ADHD stimulant medication compared with the total and
matched groups not receiving ADHD medication at year 4.1394The reason for this difference among patients with GHD is
not clear because both groups were receiving GH at similar
doses, and this observation remained after matching the 2
groups for baseline measurements. Notwithstanding the dif-
ferences in diagnosis, the potentially positive effects of GH
treatment on maintaining weight and BMI are consistent
with studies that showed greater weight gain in pediatric pa-
tients with chronic renal failure who received GH treat-
ment.21,22
TheDHSDS andDBMI SDS outcomes in the current study
suggest that psychostimulant medication treatment for
ADHD does not negatively impact the linear growth response
to GH therapy in pediatric patients. The current study find-
ings support the speculation that GH treatment may provide
a protective effect on weight maintenance and linear growth
in patients with short stature in the context of ADHD treat-
ment with stimulant medication.
Previous studies that examined height outcomes in chil-
dren treated with GH with or without treatment with
ADHD medications are limited to 2 studies from the
NCGS registry, 1 study from the KIGS registry, and a smaller
study (n = 78) examining SGA children treated with GHwith
or without methylphenidate treatment for ADHD.6,11,12,14
Using previously developed growth prediction models, the
KIGS study found that children with GHD and ADHD
who were receiving stimulant medication grew less than
would be expected for patients with GHD in the first year
of GH treatment (GHD 1.1 cm, P < .05). The children
with and without ADHD differed significantly on several
baseline characteristics, some of which were statistically
controlled for in the growth prediction models. These differ-
ences in baseline characteristics between children with and
without ADHDmay play a critical role in the observed differ-
ences in linear growth in statistically controlled analyses
compared with analyses using matched samples, as was
shown in the current study. The findings of the current study
support and extend the earlier NCGS studies with the inclu-
sion of additional GH diagnostic groups beyond ISS and
GHD, and comparison with a group not receiving ADHD
stimulant medication matched to baseline age, sex, height,
weight, and BMI. The current study also adds the novel sug-
gestion that GH treatment may stabilize BMI in patients who
are receiving ADHD stimulant medication. The stabilization
of BMI may support the improved linear growth response to
GH in these patients who are at risk for weight loss and poor
linear growth.7-9 Similar to the current study, the groups
receiving and not receiving ADHD stimulant medication
from the NCGS registry studies showed significant differ-
ences in baseline characteristics, including age, sex, and
BMI.6,11 Statistical analyses were used to control for these
baseline differences. As was found in the current study, a
small difference in DHSDS (0.17 SDS11 and 0.4 cm/y6)
was observed during GH treatment in patients with GHD
receiving ADHD stimulant medication compared with chil-
dren with GHD not receiving stimulant medications, the de-
gree of which would not be consistent with an unsatisfactory
growth response to GH treatment3,4 and is not likely to beRose et al
December 2015 ORIGINAL ARTICLESclinically meaningful. More importantly, in the current study
it was shown that matching the groups receiving and not
receiving ADHD stimulant medication on baseline charac-
teristics of age, height, weight, BMI, and sex resulted in no
observed difference in the linear growth response to GH
treatment. Additionally, replacing chronological age with
baseline bone age as a covariate in the analyses did not alter
the linear growth outcomes between the matched groups
receiving and not receiving ADHD stimulant medication.
Strengths of the current study include the real-world anal-
ysis of GH treatment in a large sample of GH treatment-naive
patients aged #18 years using data from the non-
interventional ANSWER Program study. Differences were
seen at baseline between the groups receiving and not
receiving ADHD stimulant medication in age, height, weight,
and sex. As in a previous registry study examining the influ-
ence of ADHD medication use on growth outcomes in pedi-
atric patients with GH treatment, the analyses were adjusted
for baseline differences between groups, particularly with re-
gard to age and corresponding measurements, to remove
possible confounding effects.6 An additional strength of the
current study is the analysis of the comparison of patients
receiving ADHD stimulant medication with a subgroup of
patients not receiving ADHD stimulant medication of
similar number who were matched for baseline age, height,
weight, BMI, and sex. This additional analysis abrogated
the differences observed between the patients receiving
ADHD stimulant medication and unmatched group not
receiving ADHD medication.
Limitations of the current study include the small number
of patients in several of the GH treatment diagnostic groups
as this prevented the statistical and matched comparisons
among all of the individual diagnostic groups. As data
continue to accumulate in the ANSWER Program, compar-
isons among these diagnostic groups will be examined. Addi-
tionally, consistent with the real-world analysis of patients
receiving GH treatment, the mean baseline HSDS in the cur-
rent study suggests some of the children may have had sub-
normal height velocity or growth failure rather than short
stature, resulting in a less than homogeneous population
relative to HSDS. For example, the analyses of height
included children younger than 2 years of age who may not
have exhibited short stature yet, but may have met other
criteria for GH treatment. Whether patients diagnosed by
their treating physicians with GHD received sex steroid prim-
ing prior to GH stimulation testing is not captured by the
registry, thus limiting the evaluation of whether GHD may
be misclassified for some patients in the registry. With regard
to psychostimulant medications, specific ADHDmedications
may differ in their effect on growth. Further studies are
needed to examine possible differences in GH treatment-
related height and weight outcomes that may be associated
with varying concomitant ADHDmedication agents, dosing,
and treatment regimens.
In patients who are treated with GH, those receiving
concomitant ADHD medication achieved a slightly lower
DHSDS over 4 years compared with patients not being treatedAttention-Deficit/Hyperactivity Disorder Medication Treatment Im
from the ANSWER Program, a Non-Interventional Studywith ADHDmedication. However, this difference disappeared
when patients were matched for baseline age, height, weight,
BMI, and sex. The vast majority of children treated with GH
achieved height within the normal range with no difference
noted between those taking and not taking ADHDmedication.
BMI was maintained in children receiving ADHDmedication
and GH therapy. These findings indicate that the treatment of
ADHDwith stimulant medication should not be a deterrent to
appropriate GH use in children. As in children not receiving
ADHD medication, GH doses in children being treated with
ADHD medication should be based on individual growth re-
sponses and avoidance of side effects. Future studies with a
longer period of treatment are warranted. n
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